Diaceutics PLC (AIM:DXRX)
London · Delayed Price · Currency is GBP · Price in GBX 147.56
+1.06 (0.72%)
Sep 4, 2026, 4:08 PM GMT
Diaceutics Cash Flow Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 0.1 | -1.7 | -1.75 | 0.72 | 0.56 |
Depreciation & Amortization | 4.33 | 3.16 | 3.27 | 1.66 | 1.02 |
Other Amortization | 1.48 | 1.47 | 1.5 | 1.35 | 0.78 |
Loss (Gain) From Sale of Assets | - | - | 0 | - | - |
Asset Writedown & Restructuring Costs | - | 0.09 | - | - | - |
Stock-Based Compensation | 0.92 | 1.02 | 0.45 | 0.54 | 0.37 |
Other Operating Activities | -1.14 | -2.08 | -0.62 | 1.16 | -0.51 |
Change in Accounts Receivable | -5.15 | -4.68 | -2.16 | -1.59 | -1.5 |
Change in Accounts Payable | 0.64 | 3.37 | 0.62 | 1.27 | -0.16 |
Operating Cash Flow | 1.18 | 0.65 | 1.31 | 5.1 | 0.57 |
Operating Cash Flow Growth | 81.11% | -50.34% | -74.27% | 794.03% | 125.30% |
Investing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.07 | -0.1 | -0.13 | -0.19 | -0.57 |
Sale (Purchase) of Intangibles | -6.38 | -4.53 | -4.73 | -4.68 | -5.04 |
Other Investing Activities | 0.32 | 0.6 | 0.65 | 0.11 | - |
Investing Cash Flow | -6.13 | -4.03 | -4.21 | -4.76 | -5.6 |
Financing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | -0.33 | -0.2 | -0.18 | -0.16 | -0.05 |
Net Debt Issued (Repaid) | -0.33 | -0.2 | -0.18 | -0.16 | -0.05 |
Issuance of Common Stock | - | 0.14 | - | 0.13 | - |
Repurchase of Common Stock | - | - | -0.05 | -0.1 | -0.17 |
Other Financing Activities | - | -0 | -0.01 | -0.06 | -0.06 |
Financing Cash Flow | -0.33 | -0.06 | -0.24 | -0.19 | -0.27 |
Net Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -0.12 | -0.48 | -0.04 | 0.02 | -0.28 |
Net Cash Flow | -5.4 | -3.92 | -3.17 | 0.17 | -5.58 |
Free Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1.11 | 0.55 | 1.19 | 4.91 | 0.01 |
Free Cash Flow Growth | 101.09% | -53.54% | -75.84% | 98100.00% | -95.69% |
Free Cash Flow Margin | 2.88% | 1.71% | 5.00% | 25.17% | 0.04% |
Free Cash Flow Per Share | 0.01 | 0.01 | 0.01 | 0.06 | - |
Levered Free Cash Flow | -4.08 | -2.35 | -1.18 | -0.35 | -5.55 |
Unlevered Free Cash Flow | -4.05 | -2.31 | -1.14 | -0.28 | -5.49 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | - | 0 | 0.01 | 0.06 | 0.06 |
Cash Income Tax Paid | 1.02 | 1.33 | -0.69 | -1.39 | 0.33 |
Change in Working Capital | -4.51 | -1.3 | -1.54 | -0.33 | -1.66 |